Answer
Headache is a very common adverse reaction with ravulizumab (affecting at least 1 in 10 patients), reported in 30.6%.
Sources for this answer
- Ultomiris 300 mg/3 mL and 1100 mg/11 mL PLGB 31187/0007Alexion Pharma UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 12Document updated
Sources checked